{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:46:29Z","timestamp":1791103589777,"version":"4.1.0"},"reference-count":58,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T00:00:00Z","timestamp":1288051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:p>\n                    Bromocriptine is an ergot alkaloid dopamine D\n                    <jats:sub>2<\/jats:sub>\n                    receptor agonist that has been used extensively in the past to treat hyperprolactinaemia, galactorrhoea and Parkinsonism. It is known that hypothalamic hypodopaminergic states and disturbed circadian rhythm are associated with the development of insulin resistance, obesity and diabetes in animals and humans. When administered in the early morning at the start of the light phase, a new quick release (QR) formulation of bromocriptine appears to act centrally to reset circadian rhythms of hypothalamic dopamine and serotonin and improve insulin resistance and other metabolic abnormalities. Phase II and III clinical studies show that QR\u2010bromocriptine lowers glycated haemoglobin by 0.6\u20131.2% (7\u201313 mmol\/mol) either as monotherapy or in combination with other antidiabetes medications. Apart from nausea, the drug is well tolerated. The doses used to treat diabetes (up to 4.8 mg daily) are much lower than those used to treat Parkinson's disease and have not been associated with retroperitoneal fibrosis or heart valve abnormalities. QR\u2010bromocriptine (Cycloset\u2122) has recently been approved in the USA for the treatment of type 2 diabetes mellitus (T2DM). Thus, a QR formulation of bromocriptine timed for peak delivery in the early morning may provide a novel neurally mediated approach to the control of hyperglycaemia in T2DM.\n                  <\/jats:p>","DOI":"10.1111\/j.1463-1326.2010.01304.x","type":"journal-article","created":{"date-parts":[[2010,9,28]],"date-time":"2010-09-28T01:01:23Z","timestamp":1285635683000},"page":"1048-1057","source":"Crossref","is-referenced-by-count":92,"title":["Bromocriptine: old drug, new formulation and new indication"],"prefix":"10.1111","volume":"12","author":[{"given":"R. I. G.","family":"Holt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. H.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. J.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,10,26]]},"reference":[{"key":"e_1_2_16_2_2","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation.","year":"2009"},{"key":"e_1_2_16_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"e_1_2_16_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.56.651.11"},{"key":"e_1_2_16_5_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.10.1683"},{"key":"e_1_2_16_6_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903501544"},{"key":"e_1_2_16_7_2","first-page":"153","volume-title":"Lisuride and Other Dopamine Agonists.","author":"Burns RS","year":"1983"},{"key":"e_1_2_16_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03189581"},{"key":"e_1_2_16_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.95"},{"key":"e_1_2_16_10_2","first-page":"60.","article-title":"Chiens rendus diabetiques.","volume":"1","author":"Bernard C.","year":"1850","journal-title":"Com Rend Soc Biol (Paris)"},{"key":"e_1_2_16_11_2","first-page":"464","article-title":"Circadian rhythms regulate the expression of the thrifty genotype\/phenotype.","volume":"4","author":"Meier AH","year":"1996","journal-title":"Diabetes Rev"},{"key":"e_1_2_16_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1201"},{"key":"e_1_2_16_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn0602-861"},{"key":"e_1_2_16_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm873"},{"key":"e_1_2_16_15_2","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00003.2009"},{"issue":"2","key":"e_1_2_16_16_2","first-page":"E246","article-title":"Evidence for a circadian rhythm of insulin secretion.","volume":"271","author":"Boden G","year":"1996","journal-title":"Am J Physiol"},{"key":"e_1_2_16_17_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.41.6.750"},{"key":"e_1_2_16_18_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.11.2182"},{"key":"e_1_2_16_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.45.8.1044"},{"key":"e_1_2_16_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006696"},{"key":"e_1_2_16_21_2","doi-asserted-by":"publisher","DOI":"10.1139\/y04-025"},{"key":"e_1_2_16_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2007.10.008"},{"key":"e_1_2_16_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01038.x"},{"key":"e_1_2_16_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0800636"},{"key":"e_1_2_16_25_2","doi-asserted-by":"publisher","DOI":"10.3132\/dvdr.2008.015"},{"key":"e_1_2_16_26_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399407000245"},{"key":"e_1_2_16_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.2519"},{"key":"e_1_2_16_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/75484"},{"key":"e_1_2_16_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/1743-7075-5-35"},{"key":"e_1_2_16_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-7-3"},{"key":"e_1_2_16_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(95)90041-1"},{"key":"e_1_2_16_32_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4267-08.2009"},{"key":"e_1_2_16_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2006.05.036"},{"key":"e_1_2_16_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0899-9007(00)00449-4"},{"key":"e_1_2_16_35_2","doi-asserted-by":"publisher","DOI":"10.1159\/000122379"},{"key":"e_1_2_16_36_2","first-page":"2912","article-title":"Influence of prolactin on dopaminergic neuronal systems in the hypothalamus.","volume":"39","author":"Moore KE","year":"1980","journal-title":"Fed Proc"},{"key":"e_1_2_16_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0149-7634(95)00018-6"},{"key":"e_1_2_16_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1990.tb00908.x"},{"key":"e_1_2_16_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1978.tb03568.x"},{"key":"e_1_2_16_40_2","doi-asserted-by":"publisher","DOI":"10.1159\/000054344"},{"key":"e_1_2_16_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)90530-5"},{"key":"e_1_2_16_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/308065a0"},{"key":"e_1_2_16_43_2","doi-asserted-by":"publisher","DOI":"10.1081\/CBI-100101040"},{"key":"e_1_2_16_44_2","doi-asserted-by":"publisher","DOI":"10.1159\/000054415"},{"key":"e_1_2_16_45_2","doi-asserted-by":"publisher","DOI":"10.1159\/000177551"},{"key":"e_1_2_16_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0800893"},{"issue":"2","key":"e_1_2_16_47_2","first-page":"E285","article-title":"Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters.","volume":"264","author":"Cincotta AH","year":"1993","journal-title":"Am J Physiol"},{"key":"e_1_2_16_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01930467"},{"key":"e_1_2_16_49_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.11.1697"},{"key":"e_1_2_16_50_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.7.1039"},{"key":"e_1_2_16_51_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00567.2005"},{"key":"e_1_2_16_52_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.19.6.667"},{"key":"e_1_2_16_53_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.8.1154"},{"key":"e_1_2_16_54_2","doi-asserted-by":"publisher","DOI":"10.1159\/000078932"},{"key":"e_1_2_16_55_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2009"},{"key":"e_1_2_16_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1983.tb03200.x"},{"key":"e_1_2_16_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-8411(05)80045-9"},{"key":"e_1_2_16_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062222"},{"key":"e_1_2_16_59_2","unstructured":"US Food and Drug Administration.Cycloset FDA label.Available from URL:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020866lbl.pdf. Accessed 8 September 2010."}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2010.01304.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2010.01304.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:14:29Z","timestamp":1761873269000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2010.01304.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,26]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1111\/j.1463-1326.2010.01304.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01304.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,26]]}}}